Evidence mapPaperPMID 40109902Full record

ArticleFrontiers in chemistry2025

Dawei Qian, Dongsheng Zha, Yuanyao Sang, Jiangquan Tao, Youshuang Cheng

Abstract read
In one paragraph

Article in Frontiers in chemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. HarnessingInternational journal of molecular sciences · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Dawei QianDepartment of Thoracic Surgery, Tongling Yi'an District People's Hospital, Tongling, Anhui, China.
Dongsheng ZhaDepartment of Thoracic Surgery, Tongling Yi'an District People's Hospital, Tongling, Anhui, China.
Yuanyao SangDepartment of Thoracic Surgery, Tongling Yi'an District People's Hospital, Tongling, Anhui, China.
Jiangquan TaoDepartment of Thoracic Surgery, Tongling Yi'an District People's Hospital, Tongling, Anhui, China.
Youshuang ChengDepartment of Thoracic Surgery, Shanghai Ninth People's Hospital, Shanghai Jiaotong University, Shanghai, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Gold nanoparticles (Au-NPs) hold significant promise in lung cancer treatment due to their unique physicochemical properties, enabling targeted drug delivery, enhanced therapeutic efficacy, and reduced systemic toxicity. This study is aimed to produce the Au-NPs utilising Methods: The synthesis of Au-NPs was carried out by combining 10 mL of an aqueous extract of M. oleifera with 190 mL of a 1 mM HAuCl4 solution. The synthesized Au-NPs were characterised using several microscopic and spectroscopic techniques. The evaluation of the median inhibitory concentration (IC50) of Au-NPs and its impact on apoptosis was conducted through the measurement of caspase activation and the formation of reactive oxygen species (ROS). Anti-cancer characteristics was conducted by employing DAPI staining. Furthermore, the influence on ROS production and mitochondrial membrane potential was evaluated at the IC50 concentration using fluorescence microscopy, employing DCFH-DA and Rhodamine 123 dyes. Results: The synthesis of Au-NPs was confirmed through UV-Vis spectroscopy, with an absorbance peak at 540 nm. FTIR, TEM results showed that the Discussion: The study demonstrates that M. oleifera-mediated Au-NPs exhibit significant cytotoxic and apoptotic effects on A549 lung cancer cells, with an IC50 value of 50 μg/mL. Both tested concentrations showed substantial anti-cancer properties, as confirmed by DAPI staining. The unique focus on lung cancer, specifically the A549 cell line, sets this study apart from others that address a broader spectrum of cancer types. These findings suggest that M. oleifera-mediated Au-NPs hold promise for clinical applications in lung cancer treatment, providing a potential new therapeutic application.

Indexed as

A549 lung cancer cell lineanti-cancercytotoxicitygold nanoparticlesmitochondrial damageMoringa oleiferaROS production

Identifiers

PMID40109902
PMCPMC11920177

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.